GlassScriptPhysician profile
Kenya D Blake Codrington
NPI 1750940466
$2,573.31
in general payments reported to CMS, 2019-2025
20 companies · $576 in 2025
The $576 reported for 2025 was more than what 97% of Neonatal (Nurse Practitioner) providers received nationally (typical 2025 total: $40.24).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $502 · 2023: $542 · 2024: $954 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,896 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,895.77 |
| Education | $175.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $554.34 | 2022-2025 | Keytruda |
| Abbvie INC. | $363.63 | 2022-2025 | |
| Janssen Biotech, INC. | $268.34 | 2024-2025 | Rybrevant, Carvykti |
| Astrazeneca Pharmaceuticals LP | $252.02 | 2023-2024 | Lynparza, Calquence, Enhertu |
| Lilly USA, LLC | $248.25 | 2022-2025 | Jaypirca, Verzenio |
| Astellas Pharma US INC | $175.98 | 2025 | |
| Sumitomo Pharma America, INC. | $173.70 | 2023-2025 | Myfembree, Gemtesa |
| Seagen INC. | $119.70 | 2023 | Adcetris |
| E.R. Squibb & Sons, L.L.C. | $105.54 | 2022-2025 | Opdivo |
| Exelixis INC. | $51.21 | 2024-2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $36.71 | 2023 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $34.40 | 2024 | Alunbrig |
| Gilead Sciences, INC. | $33.44 | 2024 | Trodelvy |
| Mirati Therapeutics, INC. | $28.97 | 2023 | Krazati |
| Janssen Pharmaceuticals, INC | $28.02 | 2023 | Xarelto |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $24.93 | 2024 | Ultomiris |
| Glaxosmithkline, LLC. | $23.34 | 2024 | Jemperli |
| 180 Medical, INC. | $20.76 | 2024 | Gentlecath |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.33 | 2025 | Caplyta |
| Millicent US INC | $14.70 | 2024 | Femring, Intrarosa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenya Blake Codrington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.